PDCD1 and cancer: In a systematic review, of 73 HIV-infected patients who received ICI therapy for advanced cancer, anti-PD-1 monotherapy was the most frequently employed regimen (n=62).19 In this cohort, grade III or higher irAEs were observed in 8.6% of patients.